FDAnews
www.fdanews.com/articles/195244-dermira-nabs-fast-track-designation-for-lebrikizumab

Dermira Nabs Fast Track Designation for Lebrikizumab

December 20, 2019

Dermira gained fast track designation from the FDA for its novel, investigational drug lebrikizumab for treatment of moderate-to-severe atopic dermatitis.

Lebrikizumab is currently being evaluated in two Phase 3 studies designed to confirm its safety and efficacy in patients ages 12 years and older.

Moderate-to-severe atopic dermatitis is characterized by a range of symptoms, including rashes that often cover much of the body and persistent itching.

View today's stories